Drug intelligence / Profile preview

miR-124-3p.1 mimics

Development stage
Preclinical
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Transfection (in Vitro), Intratumoral (preclinical Models, In Vivo)
01

Overview

miR-124-3p.1 mimics are synthetic, chemically modified oligonucleotides designed to functionally imitate the endogenous microRNA miR-124-3p.1. These mimics upregulate cellular miR-124-3p.1 activity and have been used experimentally to study and modulate gene regulation in vitro and in vivo. In cancer research, especially in hepatocellular carcinoma (HCC), miR-124-3p.1 mimics demonstrate tumor-suppressive functions by sensitizing cancer cells to sorafenib and by inducing apoptosis through downregulation of SIRT1 and modulation of the AKT2 pathway. In preclinical models, administration of miR-124-3p.1 mimics has achieved reduced tumor proliferation and enhanced therapeutic efficacy of sorafenib. The use of such mimics remains experimental and has not reached regulatory approval for clinical use[3][4].

Other names
miR-124-3p.1 mimicmiR124-3p.1 mimicmiR 124-3p.1 mimicmiRNA-124-3p.1 mimicsmiRNA124-3p.1 mimicsmiRNA 124-3p.1 mimics
02

Targets

Alpha-actinin-4 mRNA 3' untranslated regionPlectin mRNA 3' untranslated region (PLEC mRNA 3' UTR)AHR (Aryl hydrocarbon receptor)Myosin heavy chain 9 mRNA 3' untranslated region (MYH9 mRNA 3' UTR)Sirtuin 1 mRNA 3' untranslated region (SIRT1 mRNA 3' UTR)

Beyond the preview

Go deeper on miR-124-3p.1 mimics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-124-3p.1 mimics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call